Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV Replication Inhibitor
SSAA09E2 is an inhibitor of SARS-CoV replication, specifically targeting the early interactions between the SARS spike protein (S) and its receptor, Angiotensin Converting Enzyme-2 (ACE2). This compound exhibits significant antiviral activity, making it a valuable tool for research into therapeutic strategies against SARS-CoV infections. Its application in studying viral entry mechanisms and potential treatments provides critical insights into coronavirus-related diseases. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-13 is a potent inhibitor of SARS-CoV-2 with a reported IC50 of 0.057 μM. As a niclosamide analogue, it demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may lead to improved bioavailability and longer half-life upon oral administration. This compound is valuable for research applications focused on antiviral therapies and understanding SARS-CoV-2 inhibition mechanisms. -
SARS-CoV-2 3CL Proteas Inhibitor
SARS-CoV-2 3CLpro-IN-13 is a highly effective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 21 nM. This compound demonstrates significant anti-coronavirus activity, making it a valuable tool for research focused on SARS-CoV-2 inhibition and antiviral drug development. It is suitable for studies investigating the biochemical mechanisms underlying coronavirus replication and the potential therapeutic strategies against SARS-CoV-2. -
SARS-CoV PLpro Substrate
Z-Arg-Leu-Arg-Gly-Gly-AMC is a synthetic peptide substrate specifically designed for the SARS-CoV PLpro enzyme. This compound facilitates the study of PLpro's proteolytic activity and its role in viral replication. It serves as a valuable tool for researchers investigating the molecular mechanisms of SARS-CoV and developing potential antiviral strategies. -
SARS-CoV-2 PLpro and Mpro Inhibitor
LY1 is a selective covalent inhibitor targeting the SARS-CoV-2 proteases PLpro and Mpro, demonstrating Kd values of 1.5 μM and 2.3 μM for Mpro C145A and PLpro C111A, respectively. It exhibits potent antiviral activity with IC50 values of 0.12 μM against Mpro and 0.99 μM against PLpro. Additionally, LY1 showcases high selectivity, distinguishing itself from other kinases, human proteases, and metalloenzymes, making it a valuable tool for research into SARS-CoV-2 protease inhibition. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-86 is an inhibitor targeting the methyltransferases nsp14 and nsp16 of SARS-CoV-2. This compound, a derivative of Andrographolide, demonstrates significant antiviral activity with low toxicity, evidenced by a predicted LD50 of 700 mg/kg. It serves as a valuable research tool for studying SARS-CoV-2 replication and may contribute to therapeutic strategies against COVID-19. -
SARS-CoV-2 Main Protease Inhibitor
X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro), displaying an affinity with a Kd value of 0.057 μM. This compound effectively disrupts the proteolytic activity of Mpro, crucial for viral replication. X77 is primarily utilized in research applications aimed at understanding SARS-CoV-2 biology and developing antiviral therapeutics. -
SARS-CoV 3CLpro Inhibitor
GRL-0496 is a potent inhibitor of SARS-CoV 3CLpro, functioning through targeting the viral protease essential for replication. It demonstrates significant enzyme inhibition with an IC50 of 30 nM and exhibits antiviral activity with an EC50 of 6.9 μM against SARS-CoV. This compound is valuable for research into antiviral therapies and the development of inhibitors aimed at addressing coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
CCF0058981 is a noncovalent inhibitor targeting the SARS-CoV-2 3CL protease (3CLpro), with an IC50 of 68 nM. This compound also demonstrates activity against the SARS-CoV-1 3CLpro, exhibiting an IC50 of 19 nM. CCF0058981 shows promising antiviral efficacy and is a valuable tool for research applications focused on COVID-19 and coronavirus protease inhibition. -
SARS-CoV-2 Mpro Inhibitor
TKB245 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating significant efficacy in preventing viral replication. This compound is effective in VeroE6 cells, making it a valuable tool for research on COVID-19 pathogenesis and therapeutics. Its role in protease inhibition provides insight into potential antiviral strategies against SARS-CoV-2. -
SARS-CoV-2 inhibitor
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor that functions by inhibiting the SKP2 protein and stabilizing BECN1. With an EC50 value of 1 μM, this compound demonstrates significant antiviral activity against SARS-CoV-2. It is suitable for research applications focusing on viral pathogenesis and the development of therapeutic strategies targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
CDD-1845 is a potent non-covalent, non-peptide inhibitor of SARS-CoV-2 main protease (Mpro) with a Ki of 3 nM. This compound effectively inhibits various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1845 is intended for research applications focused on SARS-CoV-2 protease inhibition and therapeutic development against COVID-19. -
SARS-CoV-2 Inhibitor
Kobophenol A is an oligomeric stilbene that acts as a SARS-CoV-2 inhibitor by hindering the interaction between the ACE2 receptor and the S1-RBD, exhibiting an IC50 value of 1.81 μM. This compound effectively blocks viral infection in cellular models, with an EC50 of 71.6 μM. Additionally, Kobophenol A demonstrates inhibitory activity against partially purified rat brain protein kinase C (PKC), with an IC50 of 52 µM, making it a valuable tool for studies on viral pathogenesis and enzyme regulation. -
SARS-CoV-2 Inhibitor
PAV-104 is an identified inhibitor of SARS-CoV-2, targeting the nucleocapsid (N) protein. By disrupting the oligomerization of the nucleocapsid, PAV-104 effectively interferes with viral particle assembly, thereby impeding replication at a multiplicity of infection (MOI) of 0.01. This compound is a valuable tool for research into antiviral strategies and the mechanistic understanding of SARS-CoV-2 propagation. -
SARS-CoV-2 Inhibitor
MAT-POS-e194df51-1 is an orally active non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 37 nM. This compound exhibits significant cytotoxicity, demonstrated by EC50 values of 64 nM in A549-ACE2-TMPRSS2 cells and 126 nM in HeLa-ACE2 cells. MAT-POS-e194df51-1 can be utilized in research focusing on antiviral drug development and the pathway exploration of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Main Protease Inhibitor
(Rac)-X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro). It demonstrates strong binding affinity with a Kd value of 0.057 μM, making it valuable for research into antiviral strategies against SARS-CoV-2. This compound is useful for studying protease inhibition mechanisms and developing therapeutic interventions targeting viral replication. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-6 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 73 nM. This compound is critical for research focused on developing antiviral therapeutics against SARS-CoV-2 by targeting its main protease, which is essential for viral replication. Its efficacy makes it suitable for studies aimed at understanding the enzymatic mechanisms of the virus and the development of potential treatment strategies. -
SARS-CoV-2 3CL Protease Inhibitor
MK-7845 is a reversible covalent inhibitor targeting the 3CL protease of SARS-CoV-2, exhibiting an IC50 of 8.7 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the research of COVID-19 therapeutics. Its specificity for the 3CL protease supports investigations into the inhibition of viral replication and pathogenesis, facilitating the development of effective antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-14 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.39 μM. This compound is a niclosamide analogue, demonstrating enhanced stability in human plasma and liver S9 enzyme assays compared to niclosamide. Due to these properties, SARS-CoV-2-IN-14 may offer improved bioavailability and prolonged half-life when administered orally, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
GRL-1720 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 value of 15 µM. This compound exhibits significant anti-SARS-CoV-2 activity, making it a valuable tool for research related to coronavirus infection and therapeutics targeting viral replication. Its efficacy in inhibiting Mpro highlights its potential use in the development of antiviral strategies against SARS-CoV-2. -
SARS-CoV Inhibitor
Ivermectin B1a is a potent inhibitor of SARS-CoV, targeting viral replication. As a derivative of Avermectin B1a, it demonstrates significant antiviral activity and is explored as a potential therapeutic candidate against SARS-CoV-2 and COVID-19. This compound serves as an important tool in research aimed at understanding and combating viral infections. -
SARS-CoV Inhibitor
SARS-CoV-IN-1 is a potent inhibitor of SARS-CoV replication, demonstrating significant antiviral activity with an EC50 of 4.9 μM in Vero cells. Additionally, SARS-CoV-IN-1 displays inhibitory effects on the 3D7 and W2 strains of Plasmodium falciparum, with IC50 values of 15.4 nM and 133.2 nM, respectively. This compound is valuable for research applications focused on both antimalarial and antiviral therapies. -
SARS-CoV Inhibitor
Ivermectin B1b is a minor component of Ivermectin with notable activity as a SARS-CoV inhibitor. This compound has demonstrated the ability to inhibit the replication of SARS-CoV-2 in cell culture, making it a valuable reagent for research applications focused on viral infection and antiviral drug development. Its anti-parasitic properties further enhance its relevance in studies addressing a wide range of biological processes. -
HIV/SARS-CoV Inhibitor
2-Hydroxyacetophenone is an inhibitor targeting HIV and SARS-CoV. This compound exhibits significant antiviral activity, making it a valuable tool for research in the development of therapeutic strategies against these viral infections. Additionally, it serves as a versatile building block for synthesis in various chemical applications. -
SARS-CoV Inhibitor
SARS-CoV-IN-3 is a potent inhibitor of SARS-CoV replication, demonstrating anti-Coronavirus activity with an EC50 value of 3.6 μM in Vero cells. Additionally, it exhibits antimalarial properties against P. falciparum strains 3D7 and W2, with IC50 values of 11.7 nM and 20.4 nM, respectively. SARS-CoV-IN-3 also effectively mitigates HIV-1-induced cytopathic effects, yielding an EC50 of 10 μM in MT-4 cells. This compound is valuable for research in virology and parasitology. -
SARS-CoV Inhibitor
SARS-CoV-IN-2 is a potent inhibitor of SARS-CoV replication, demonstrating anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. Additionally, it exhibits significant inhibition of P. falciparum strains, showing IC50 values of 21.5 nM and 30 nM for the 3D7 and W2 strains, respectively. SARS-CoV-IN-2 also mitigates HIV-1-induced cytopathic effects, with an EC50 of 2.9 μM in MT-4 cells. This compound is valuable for research applications targeting both antiviral and antimalarial activities. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir is a potent inhibitor of Hepatitis C virus (HCV) replication with demonstrated efficacy against SARS-CoV-2. This orally active compound exhibits significant antiviral activity in vitro, achieving an effective concentration (EC90) of 0.47 μM against COVID-19. Bemnifosbuvir displays pangenotypic activity, making it a valuable tool for research into antiviral therapies for both HCV and SARS-CoV-2 infections. -
HCV/SARS-CoV-2 Inhibitor
Bemnifosbuvir hemisulfate is a potent inhibitor of HCV viral replication and a promising antiviral agent against SARS-CoV-2. This guanosine nucleotide proagent exhibits significant efficacy in vitro, demonstrating an EC90 value of 0.47 μM against COVID-19. Bemnifosbuvir hemisulfate also shows pangenotypic antiviral activity, making it a valuable tool for research in viral infections and therapeutic development. -
PPT1 Inhibitor
Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders. -
SARS-CoV-2 PLpro Inhibitor
Aloin B (Isobarbaloin) is an orally active inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with reported IC50 values of 16.08 μM for hydrolytic activity and 17.51 μM for deubiquitinase activity. This compound demonstrates biological activity in anti-inflammatory pathways and tumor promotion inhibition, making it valuable for research in cancer biology and COVID-19. Additionally, Aloin B is metabolized by intestinal flora to produce aloe-emodin-9-anthrone, which may contribute to its laxative effects.
